Bristol-Myers Squibb (BMY)

• Market cap: $90.7B
• 1 day: -3.02%
• 5 days: -9.15%
• 1 month: -3.67%
• 3 months: -11.18%
• 6 months: -24.36%
• Year to date: -21.48%
• 1 year: -6.24%
• 5 years: -23.99%
• 10 years: -32.07%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Employees: 34,100

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

20% more first-time investments, than exits

New positions opened: 198 | Existing positions closed: 165

6% more capital invested

Capital invested by funds: $91.5B [Q4 2024] → $97.1B (+$5.66B) [Q1 2025]

2% more call options, than puts

Call options by funds: $1.73B | Put options by funds: $1.7B

0.14% less ownership

Funds ownership: 78.48% [Q4 2024] → 78.33% (-0.14%) [Q1 2025]

1% less funds holding

Funds holding: 2,445 [Q4 2024] → 2,429 (-16) [Q1 2025]

3% less repeat investments, than reductions

Existing positions increased: 935 | Existing positions reduced: 968

10% less funds holding in top 10

Funds holding in top 10: 39 [Q4 2024] → 35 (-4) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $34 24% downside
• Avg. target: $34 24% downside
• High target: $34 24% downside

1 analyst rating

• positive: 0 0%
• neutral: 0 0%
• negative: 1 100%

Morgan Stanley Terence Flynn

24% downside $34

Underweight Maintained

10 Jul 2025